The Current Scientific and Legal Status of Alternative Methods to the LD50 Test for Botulinum Neurotoxin Potency Testing

An Expert Meeting on The Current Scientific and Legal Status of Alternative Methods to the LD50 Test for Botulinum Neurotoxin (BoNT) Potency Testing was organised by the Centre for Documentation and Evaluation of Alternatives to Animal Experiments (ZEBET) at the Federal Institute for Risk Assessment (BfR), and took place on 27–28 April 2009, in Berlin, Germany. The goal of ZEBET is to promote primarily the replacement of legally required animal experiments with valid alternative test methods, to reduce the numbers of test animals used to the absolutely necessary level, and to alleviate their pain and suffering. ZEBET’s tasks are the documentation, assessment and promotion of alternative methods to animal experiments on a national and international level, and the initiation of research and development, including the funding of smaller research projects. The Expert Meeting on alternative methods for Botulinum neurotoxin (BoNT) potency testing was held at the BfR as the result of a decree from the German Federal Ministry of Food, Agriculture and Consumer Protection (BMELV), after it was informed by German state authorities about an increase in animal numbers being used in the LD50 potency test in mice for the purposes of BoNT potency testing. Ethical concerns have been raised in both Europe and the United States about the animal suffering involved in this type of testing, especially in the context of BoNT’s aesthetic applications. There had been increased public pressure on the German Government, due to successful campaigning by animal welfare/anti-vivisectionist organisations on the issue of BoNT animal testing. As a result, the BMELV asked ZEBET to assess the status of the different alternative methods to the BoNT LD50 potency test that are cited in the European Pharmacopoeia (EP) 6.0, Monograph 2113, Botulinum Toxin Type The Current Scientific and Legal Status of Alternative Methods to the LD50 Test for Botulinum Neurotoxin Potency Testing

[1]  K. Krampfl,et al.  Synaptic currents and transmitter responses in human NT2 neurons differentiated in aggregate culture , 2010, Neuroscience Letters.

[2]  M. Stern,et al.  Cellular phenotypes of human model neurons (NT2) after differentiation in aggregate culture , 2009, Cell and Tissue Research.

[3]  Anika Ashok,et al.  ICH Harmonised Tripartite Guideline , 2009 .

[4]  D. Sesardic,et al.  Measurement of botulinum types A, B and E neurotoxicity using the phrenic nerve-hemidiaphragm: improved precision with in-bred mice. , 2009, Toxicon : official journal of the International Society on Toxinology.

[5]  S. Dodd,et al.  The in vivo rat muscle force model is a reliable and clinically relevant test of consistency among botulinum toxin preparations. , 2008, Toxicon : official journal of the International Society on Toxinology.

[6]  K. Shakesheff,et al.  The Intercostal NMJ Assay — A New Alternative to the Conventional LD50 Assay for the Determination of the Therapeutic Potency of Botulinum Toxin Preparations , 2008, Alternatives to laboratory animals : ATLA.

[7]  Eric A. Johnson,et al.  A neuronal cell‐based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies , 2007, FEBS letters.

[8]  François Paquet-Durand,et al.  Human model neurons in studies of brain cell damage and neural repair. , 2007, Current molecular medicine.

[9]  Dorothea Sesardic,et al.  Detection of antibodies against botulinum toxins , 2004, Movement disorders : official journal of the Movement Disorder Society.

[10]  D. Sesardic,et al.  Role for standards in assays of botulinum toxins: international collaborative study of three preparations of botulinum type A toxin. , 2003, Biologicals : journal of the International Association of Biological Standardization.

[11]  K. Aoki,et al.  A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. , 2001, Toxicon : official journal of the International Society on Toxinology.

[12]  Raymond C. Stevens,et al.  Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 Å resolution , 2000, Nature Structural Biology.

[13]  G. Schiavo,et al.  Neurotoxins affecting neuroexocytosis. , 2000, Physiological reviews.

[14]  R. Stevens,et al.  Recombinant expression and purification of the botulinum neurotoxin type A translocation domain. , 1997, Protein expression and purification.

[15]  D Sesardic,et al.  Recombinant SNAP-25 is an effective substrate for Clostridium botulinum type A toxin endopeptidase activity in vitro. , 1997, Microbiology.

[16]  K. Wohlfarth,et al.  Botulinum A toxins: units versus units , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[17]  D. Sesardic,et al.  Therapeutic botulinum type A toxin: factors affecting potency. , 1996, Toxicon : official journal of the International Society on Toxinology.

[18]  R. G. Das,et al.  Refinement and validation of an alternative bioassay for potency testing of therapeutic botulinum type A toxin. , 1996, Pharmacology & toxicology.

[19]  G. Schiavo,et al.  Botulinum neurotoxins are zinc proteins. , 1992, The Journal of biological chemistry.

[20]  J. Black,et al.  Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis , 1986, The Journal of cell biology.

[21]  J. Black,et al.  Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization , 1984, Nature.

[22]  L. Simpson The origin, structure, and pharmacological activity of botulinum toxin. , 1981, Pharmacological reviews.

[23]  Wang Yin-chun Biological characteristics and quality of botulinum toxin type A for injection , 2012 .

[24]  Kurt W Simons Open letter to the German Chancellor Dr. Angela Merkel. Council Directive on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes. , 2010, ALTEX.

[25]  J. Abraham The international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use , 2009 .

[26]  D. Sesardic,et al.  Development of improved SNAP25 endopeptidase immuno-assays for botulinum type A and E toxins. , 2008, Journal of immunological methods.

[27]  K. Roger Aoki Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. , 2002, Toxicon : official journal of the International Society on Toxinology.

[28]  TG 442D OECD GUIDELINE FOR THE TESTING OF CHEMICALS In Vitro Skin Sensitisation: ARE-Nrf2 Luciferase Test Method , 2000 .

[29]  R E Gaines Das,et al.  Validation of in vitro assays for botulinum toxin: a case study. , 1999, Developments in biological standardization.

[30]  F. Brown,et al.  Quality of biotechnological products : Stability testing of biotechnological/ biological products : International Conference on Harmonisation (ICH) , 1998 .

[31]  L. Simpson Molecular pharmacology of botulinum toxin and tetanus toxin. , 1986, Annual review of pharmacology and toxicology.

[32]  T. H. Allegri The Code of Federal Regulations , 1986 .

[33]  L. Simpson Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. , 1980, The Journal of pharmacology and experimental therapeutics.